AdvisorShares Psychedelics ETF Rating $11.61 +0.34 (+3.02%) Closing price 04:10 PM EasternExtended Trading$11.61 0.00 (0.00%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsBuy This Stock AdvisorShares Psychedelics ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PSIL Aggregate RatingModerate Buy 2.89Holdings in PSIL have an aggregate rating of Moderate Buy based on 116 analyst ratings issued in the past year covering 14 companies (72.3% of the portfolio).PSIL Aggregate Price Target$11.61High Prediction$11.61Average Prediction$11.61Low Prediction$11.61Holdings in PSIL have an aggregate price target of $11.61 and a range of $11.61 to $11.61 covering 14 companies (72.3% of the portfolio).PSIL Consensus Ratings of HoldingsStrong Buy1 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy3 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by AdvisorShares Psychedelics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 14 PSIL Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings8.78%MNMDMind Medicine (MindMed)$5.97+7.8%2.2417 of 5 stars3.23$25.11 320.6%13Gap Down7.37%ALKSAlkermes$32.65+0.4%4.6235 of 5 stars2.69$39.38 20.6%13News CoveragePositive News7.28%SAGESage Therapeutics$7.77-1.1%3.4293 of 5 stars2.00$8.81 13.4%196.81%ATAIAtai Life Sciences$1.48+19.4%3.3736 of 5 stars3.00$9.00 508.1%4Gap Up6.57%STIMNeuronetics$3.94+4.2%2.1466 of 5 stars2.67$5.50 39.6%3Short Interest ↑Gap Down6.08%NRXPNRx Pharmaceuticals$2.01+3.6%2.7108 of 5 stars3.20$28.25 1,305.5%5Analyst ForecastNews CoverageGap Up4.93%GHRSGH Research$10.40-3.3%2.6599 of 5 stars3.00$30.86 196.7%7Gap Down4.91%VTGNVistagen Therapeutics$2.39+2.1%1.1228 of 5 stars4.0014.37%NBIXNeurocrine Biosciences$108.31+1.2%4.9224 of 5 stars2.83$165.38 52.7%23Positive News4.31%CMPSCOMPASS Pathways$3.09+10.8%3.3554 of 5 stars3.00$20.20 553.7%6High Trading Volume4.30%ITCIIntra-Cellular Therapies$131.910.0%3.5561 of 5 stars2.33$106.23 -19.5%15Analyst ForecastNews CoveragePositive NewsHigh Trading Volume3.99%NEUPNeuphoria Therapeutics Inc. - Common Stock$5.80+1.8%1.0896 of 5 stars3.00$21.00 262.1%11.67%ENVBEnveric Biosciences$1.36+3.8%2.6169 of 5 stars3.00$10.00 635.3%10.89%RLMDRelmada Therapeutics$0.30+10.8%3.8868 of 5 stars2.00$4.25 1,302.2%5Earnings ReportGap Up This page (NYSEARCA:PSIL) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AdvisorShares Psychedelics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share AdvisorShares Psychedelics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PSIL Stock Free PSIL Stock Alerts